Cargando…

Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers

The effects of inactivated SARS-CoV-2 vaccine (CoronaVac) on previously naturally infected individuals are unknown. This study compared immunogenicity and reactogenicity of CoronaVac in once naturally infected health-care workers (HCWs) and uninfected HCWs. All HCWs were immunized with two doses of...

Descripción completa

Detalles Bibliográficos
Autores principales: Soysal, Ahmet, Gönüllü, Erdem, Karabayır, Nalan, Alan, Servet, Atıcı, Serkan, Yıldız, İsmail, Engin, Havva, Çivilibal, Mahmut, Karaböcüoğlu, Metin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330011/
https://www.ncbi.nlm.nih.gov/pubmed/34324409
http://dx.doi.org/10.1080/21645515.2021.1953344
_version_ 1783732613635112960
author Soysal, Ahmet
Gönüllü, Erdem
Karabayır, Nalan
Alan, Servet
Atıcı, Serkan
Yıldız, İsmail
Engin, Havva
Çivilibal, Mahmut
Karaböcüoğlu, Metin
author_facet Soysal, Ahmet
Gönüllü, Erdem
Karabayır, Nalan
Alan, Servet
Atıcı, Serkan
Yıldız, İsmail
Engin, Havva
Çivilibal, Mahmut
Karaböcüoğlu, Metin
author_sort Soysal, Ahmet
collection PubMed
description The effects of inactivated SARS-CoV-2 vaccine (CoronaVac) on previously naturally infected individuals are unknown. This study compared immunogenicity and reactogenicity of CoronaVac in once naturally infected health-care workers (HCWs) and uninfected HCWs. All HCWs were immunized with two doses of CoronaVac (600 U/0.5 ml) intramuscularly at a 28-day interval. Adverse reactions were obtained by web-based questionnaires or telephone calls seven days after each vaccine dose. Detection of antibody levels against the receptor-binding domain (RBD) of SARS-CoV-2 spike protein was done four weeks after the second dose of the vaccine. We enrolled 103 previously naturally infected and 627 uninfected HCWs. The mean time for vaccination after the first nasopharyngeal SARS-CoV-2 positivity was 64 days (range: 15–136 days) in previously naturally infected HCWs. Among the previously naturally infected HCWs, 41 (40%) were asymptomatic, 52 (50%) had mild upper respiratory tract infections, 10 (105) had pneumonia, and only 6 (5%) were hospitalized. Any reported adverse reactions, either from the first dose or the second dose of vaccine administration, did not differ between previously infected and uninfected HCWs. Anti-RBD antibody titers were obtained in 50 (51%) of 103 previously infected HCWs and 142 (23%) of 627 uninfected HCWs. Anti-RBD antibody titers were significantly higher in HCWs with a previous natural infection (median 1220 AU/ml, range: 202–10328 AU/mL) than in uninfected HCWs (median: 913 AU/ml, range: 2.8–15547 AU/mL, p = .032). CoronaVac administration was safe and may elicit higher antibody responses in previously naturally infected individuals.
format Online
Article
Text
id pubmed-8330011
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-83300112021-08-03 Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers Soysal, Ahmet Gönüllü, Erdem Karabayır, Nalan Alan, Servet Atıcı, Serkan Yıldız, İsmail Engin, Havva Çivilibal, Mahmut Karaböcüoğlu, Metin Hum Vaccin Immunother Research Paper The effects of inactivated SARS-CoV-2 vaccine (CoronaVac) on previously naturally infected individuals are unknown. This study compared immunogenicity and reactogenicity of CoronaVac in once naturally infected health-care workers (HCWs) and uninfected HCWs. All HCWs were immunized with two doses of CoronaVac (600 U/0.5 ml) intramuscularly at a 28-day interval. Adverse reactions were obtained by web-based questionnaires or telephone calls seven days after each vaccine dose. Detection of antibody levels against the receptor-binding domain (RBD) of SARS-CoV-2 spike protein was done four weeks after the second dose of the vaccine. We enrolled 103 previously naturally infected and 627 uninfected HCWs. The mean time for vaccination after the first nasopharyngeal SARS-CoV-2 positivity was 64 days (range: 15–136 days) in previously naturally infected HCWs. Among the previously naturally infected HCWs, 41 (40%) were asymptomatic, 52 (50%) had mild upper respiratory tract infections, 10 (105) had pneumonia, and only 6 (5%) were hospitalized. Any reported adverse reactions, either from the first dose or the second dose of vaccine administration, did not differ between previously infected and uninfected HCWs. Anti-RBD antibody titers were obtained in 50 (51%) of 103 previously infected HCWs and 142 (23%) of 627 uninfected HCWs. Anti-RBD antibody titers were significantly higher in HCWs with a previous natural infection (median 1220 AU/ml, range: 202–10328 AU/mL) than in uninfected HCWs (median: 913 AU/ml, range: 2.8–15547 AU/mL, p = .032). CoronaVac administration was safe and may elicit higher antibody responses in previously naturally infected individuals. Taylor & Francis 2021-07-29 /pmc/articles/PMC8330011/ /pubmed/34324409 http://dx.doi.org/10.1080/21645515.2021.1953344 Text en © 2021 Taylor & Francis Group, LLC
spellingShingle Research Paper
Soysal, Ahmet
Gönüllü, Erdem
Karabayır, Nalan
Alan, Servet
Atıcı, Serkan
Yıldız, İsmail
Engin, Havva
Çivilibal, Mahmut
Karaböcüoğlu, Metin
Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers
title Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers
title_full Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers
title_fullStr Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers
title_full_unstemmed Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers
title_short Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers
title_sort comparison of immunogenicity and reactogenicity of inactivated sars-cov-2 vaccine (coronavac) in previously sars-cov-2 infected and uninfected health care workers
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330011/
https://www.ncbi.nlm.nih.gov/pubmed/34324409
http://dx.doi.org/10.1080/21645515.2021.1953344
work_keys_str_mv AT soysalahmet comparisonofimmunogenicityandreactogenicityofinactivatedsarscov2vaccinecoronavacinpreviouslysarscov2infectedanduninfectedhealthcareworkers
AT gonulluerdem comparisonofimmunogenicityandreactogenicityofinactivatedsarscov2vaccinecoronavacinpreviouslysarscov2infectedanduninfectedhealthcareworkers
AT karabayırnalan comparisonofimmunogenicityandreactogenicityofinactivatedsarscov2vaccinecoronavacinpreviouslysarscov2infectedanduninfectedhealthcareworkers
AT alanservet comparisonofimmunogenicityandreactogenicityofinactivatedsarscov2vaccinecoronavacinpreviouslysarscov2infectedanduninfectedhealthcareworkers
AT atıcıserkan comparisonofimmunogenicityandreactogenicityofinactivatedsarscov2vaccinecoronavacinpreviouslysarscov2infectedanduninfectedhealthcareworkers
AT yıldızismail comparisonofimmunogenicityandreactogenicityofinactivatedsarscov2vaccinecoronavacinpreviouslysarscov2infectedanduninfectedhealthcareworkers
AT enginhavva comparisonofimmunogenicityandreactogenicityofinactivatedsarscov2vaccinecoronavacinpreviouslysarscov2infectedanduninfectedhealthcareworkers
AT civilibalmahmut comparisonofimmunogenicityandreactogenicityofinactivatedsarscov2vaccinecoronavacinpreviouslysarscov2infectedanduninfectedhealthcareworkers
AT karabocuoglumetin comparisonofimmunogenicityandreactogenicityofinactivatedsarscov2vaccinecoronavacinpreviouslysarscov2infectedanduninfectedhealthcareworkers